These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 12648732)
1. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Miller TJ; Zipursky RB; Perkins D; Addington J; Woods SW; Hawkins KA; Hoffman R; Preda A; Epstein I; Addington D; Lindborg S; Marquez E; Tohen M; Breier A; McGlashan TH Schizophr Res; 2003 May; 61(1):19-30. PubMed ID: 12648732 [TBL] [Abstract][Full Text] [Related]
2. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller TJ; Woods SW; Hawkins KA; Hoffman R; Lindborg S; Tohen M; Breier A Schizophr Res; 2003 May; 61(1):7-18. PubMed ID: 12648731 [TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Woods SW; Breier A; Zipursky RB; Perkins DO; Addington J; Miller TJ; Hawkins KA; Marquez E; Lindborg SR; Tohen M; McGlashan TH Biol Psychiatry; 2003 Aug; 54(4):453-64. PubMed ID: 12915290 [TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331 [TBL] [Abstract][Full Text] [Related]
6. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Breier A; Berg PH Biol Psychiatry; 1999 Aug; 46(3):361-4. PubMed ID: 10435201 [TBL] [Abstract][Full Text] [Related]
7. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Tollefson GD; Andersen SW; Tran PV Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202 [TBL] [Abstract][Full Text] [Related]
8. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Hawkins KA; Keefe RS; Christensen BK; Addington J; Woods SW; Callahan J; Zipursky RB; Perkins DO; Tohen M; Breier A; McGlashan TH Schizophr Res; 2008 Oct; 105(1-3):1-9. PubMed ID: 18774696 [TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol treatment in first-episode psychosis. Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301 [TBL] [Abstract][Full Text] [Related]
10. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Green AI; Tohen MF; Hamer RM; Strakowski SM; Lieberman JA; Glick I; Clark WS; Schizophr Res; 2004 Feb; 66(2-3):125-35. PubMed ID: 15061244 [TBL] [Abstract][Full Text] [Related]
11. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Jones B; Taylor CC; Meehan K J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747 [TBL] [Abstract][Full Text] [Related]
14. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346 [TBL] [Abstract][Full Text] [Related]
15. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Tollefson GD; Sanger TM; Lu Y; Thieme ME Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Tohen M; Jacobs TG; Grundy SL; McElroy SL; Banov MC; Janicak PG; Sanger T; Risser R; Zhang F; Toma V; Francis J; Tollefson GD; Breier A Arch Gen Psychiatry; 2000 Sep; 57(9):841-9. PubMed ID: 10986547 [TBL] [Abstract][Full Text] [Related]
17. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736 [TBL] [Abstract][Full Text] [Related]
19. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. Sanger TM; Grundy SL; Gibson PJ; Namjoshi MA; Greaney MG; Tohen MF J Clin Psychiatry; 2001 Apr; 62(4):273-81. PubMed ID: 11379842 [TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]